CDK4/6 Inhibition Reprograms Mitochondrial Metabolism in BRAF(V600) Melanoma via a p53 Dependent Pathway

SIMPLE SUMMARY: Cyclin-dependent kinases 4 and 6 (CDK4/6) are key enzymes controlling the cell cycle. CDK4/6 inhibitors are being tested in multiple clinical trials for a range of cancers including melanoma, and a deeper understanding of how they interact with other therapies is vital for their clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Santiappillai, Nancy T., Abuhammad, Shatha, Slater, Alison, Kirby, Laura, McArthur, Grant A., Sheppard, Karen E., Smith, Lorey K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866416/
https://www.ncbi.nlm.nih.gov/pubmed/33572972
http://dx.doi.org/10.3390/cancers13030524

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866416/
https://www.ncbi.nlm.nih.gov/pubmed/33572972
http://dx.doi.org/10.3390/cancers13030524

Ejemplares similares